A Phase 1 interventional study of PF-08166744 and Placebo in Healthy Participants, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08166744) in healthy adults. This is the first time PF-08166744 will be given to people.
This study is seeking participants who:
The Investigators will compare the experiences of people receiving study medicine with those receiving placebo. This will help researchers learn about the safety and effects of study medicine.
People receiving a single dose will take part in the study for about 12 to 20 weeks. Those receiving multiple doses will take part for about 22 weeks. During the study, participants will have study visits and tests. These will help check their health and measure the amount of study medicine in their blood.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Part A will receive a single ascending dose of PF-08166744 by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple ascending subcutaneous doses of PF-08166744 according to the assigned cohort.
Drug: PF-08166744
Participants in Part A will receive a single dose of placebo by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple subcutaneous doses of placebo according to the assigned cohort.
Drug: Placebo
Participants will receive a single dose of PF-08166744 by subcutaneous or intravenous administration.
Participants will receive a single dose of placebo by subcutaneous or intravenous administration.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Vital Sign Abnormalities
Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Electrocardiogram (ECG) Abnormalities
Time frame: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of PF-08166744
Time frame: Day 1 through Day 113
SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of PF-08166744
Time frame: Day 1 through Day 113
SAD (Part A): Maximum Observed Plasma Concentration (Cmax) of PF-08166744
Time frame: Day 1 through Day 113
SAD (Part A): Time to Maximum Observed Plasma Concentration (Tmax) of PF-08166744
Time frame: Day 1 through Day 113
SAD (Part A): Terminal Elimination Half-Life (t1/2) of PF-08166744
Time frame: Day 1 through Day 113
MAD (Part B): Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau) of PF-08166744
Time frame: Day 1 through Day 127
MAD (Part B): Maximum Observed Plasma Concentration (Cmax) of PF-08166744
Time frame: Day 1 through Day 127
MAD (Part B): Time to Maximum Observed Plasma Concentration (Tmax) of PF-08166744
Time frame: Day 1 through Day 127
MAD (Part B): Terminal Elimination Half-Life (t1/2) of PF-08166744
Time frame: Day 1 through Day 127
No study locations are listed for this record.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Start is estimated for Nov 2026; primary completion for Jan 2028, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.